Burning Rock Biotech Reports Q4 and Full Year 2025 Financial Results
Written by Emily J. Thompson, Senior Investment Analyst
Updated: Mar 12 2026
0mins
Source: seekingalpha
- Quarterly Financial Performance: Burning Rock Biotech reported a Q4 GAAP EPS of -$0.02 with revenues of $18.1 million and a net loss of RMB 15.4 million (approximately $2.2 million), indicating challenges faced during the company's transition.
- Annual Revenue Growth: Total revenue for 2025 reached RMB 539.6 million ($77.2 million), representing a 4.6% increase from RMB 515.8 million in 2024, reflecting the company's stability in the overall market.
- Laboratory Business Decline: Revenue from the central laboratory business was RMB 160.0 million ($22.9 million) in 2025, an 8.9% decrease from RMB 175.6 million in 2024, primarily due to a reduction in the number of tests, indicating a shift towards in-hospital testing and pharma R&D services.
- Pharma R&D Services Growth: Revenue from pharma research and development services increased to RMB 155.5 million ($22.2 million) in 2025, a 34.5% rise from RMB 115.7 million in 2024, demonstrating increased demand for development and testing services from pharma clients.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy BNR?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on BNR
About BNR
Burning Rock Biotech Ltd is a Company principally engaged in developing and providing cancer therapy selection tests. The Company operates three businesses, including central laboratory business, in-hospital business and pharma research and development services. Central laboratory business mainly includes the sales of its cancer therapy selection test to individual patient customers. In-hospital business includes the manufacture and sales of reagent kits, as well as the provision of facilitation services for laboratory equipment sold to hospitals. The pharma research and development services include a range of cancer therapy selection test services, analytical validation services and project management services.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
Burning Rock Biotech Q1 Financial Results Analysis
- Net Loss Overview: Burning Rock Biotech reported a net loss of RMB 17.5 million (approximately $2.5 million) for Q1 2026, indicating challenges in profitability that may impact investor confidence moving forward.
- Revenue Decline: The company's revenue for the first quarter was $15.65 million, reflecting a 14.7% year-over-year decrease from $18.1 million in Q1 2025, highlighting pressures from weakened market demand and increased competition.
- GAAP EPS Report: The reported GAAP EPS was -$0.02, suggesting that the company continues to experience negative growth in profitability, which could affect its future financing capabilities and market performance.
- Historical Financial Data: Historical earnings data shows that revenue for Q1 2025 was RMB 133.1 million (approximately $19.5 million), while Q1 2026 revenue dropped to RMB 107.9 million (approximately $15.65 million), indicating a concerning trend of declining revenues.
See More
Burning Rock CEO Yusheng Han Purchases $546K in ADSs, Signaling Confidence
- Share Purchase: Yusheng Han, founder and CEO of Burning Rock Biotech, purchased 31,487 ADSs in the open market for $546,603.90, demonstrating his confidence in the company's future growth.
- Cumulative Holdings: With an additional 41,246 ADSs acquired in the previous post-earnings trading window, Han's total purchases amount to 72,733 ADSs for $1,358,325.18, reflecting his strong belief in the company's business prospects.
- Future Acquisition Plans: Han may continue to acquire the company's ADSs through open-market transactions, privately negotiated deals, or block trades, with the timing and conditions influenced by market conditions and regulatory requirements.
- Company Overview: Burning Rock focuses on next-generation sequencing technology in precision oncology, offering NGS-based therapy selection testing for late-stage cancer patients and early cancer detection, which has progressed to clinical validation, indicating significant market potential.
See More
Burning Rock Biotech Reports Q4 and Full Year 2025 Financial Results
- Quarterly Financial Performance: Burning Rock Biotech reported a Q4 GAAP EPS of -$0.02 with revenues of $18.1 million and a net loss of RMB 15.4 million (approximately $2.2 million), indicating challenges faced during the company's transition.
- Annual Revenue Growth: Total revenue for 2025 reached RMB 539.6 million ($77.2 million), representing a 4.6% increase from RMB 515.8 million in 2024, reflecting the company's stability in the overall market.
- Laboratory Business Decline: Revenue from the central laboratory business was RMB 160.0 million ($22.9 million) in 2025, an 8.9% decrease from RMB 175.6 million in 2024, primarily due to a reduction in the number of tests, indicating a shift towards in-hospital testing and pharma R&D services.
- Pharma R&D Services Growth: Revenue from pharma research and development services increased to RMB 155.5 million ($22.2 million) in 2025, a 34.5% rise from RMB 115.7 million in 2024, demonstrating increased demand for development and testing services from pharma clients.
See More
Seeking Dividends? Explore Opportunities in Europe.
U.S. Dividend Seekers: Investors in the U.S. are encouraged to explore European markets for potential dividend opportunities.
European Market Appeal: European companies are offering attractive dividend yields, which may be appealing compared to U.S. counterparts.
Economic Factors: Factors such as currency fluctuations and economic recovery in Europe are influencing the attractiveness of these investments.
Investment Strategy: Diversifying into European dividends could enhance returns for U.S. investors seeking income.
See More
Burning Rock's CEO Yusheng Han Purchases $811,721 in ADS, Signaling Confidence
- Executive Purchase Signal: CEO Yusheng Han's acquisition of $811,721 in ADS from the open market indicates his confidence in the company's future, potentially enhancing investor trust in Burning Rock.
- Compliance in Trading: This purchase was conducted in accordance with applicable regulations and the company's insider trading policy, ensuring the legality and transparency of the transaction, which further enhances corporate governance.
- Potential for Continued Purchases: Han may continue to acquire ADS depending on market conditions, and this flexible purchasing strategy could help seize investment opportunities amid market fluctuations, thereby increasing shareholder value.
- Optimistic Business Outlook: The company focuses on the application of NGS technology in precision oncology, and with its transition into the clinical validation stage, it is expected to achieve business growth, attracting more investor interest.
See More
Burning Rock Biotech Secures All Resolutions at 2025 AGM
- Auditor Appointment Confirmation: Burning Rock Biotech's 2025 AGM ratified the appointment of Ernst & Young Hua Ming LLP as the auditor for the fiscal year ending December 31, 2025, ensuring financial transparency and compliance, which is expected to enhance investor confidence.
- Board Re-election: Shareholders re-elected Feng Deng and Licen Lisa Xu as directors, indicating trust in the current management team, which is likely to support the company's ongoing development and strategic execution in the precision oncology sector.
- Resolution Execution Authorization: Shareholders authorized directors to take necessary actions to implement the passed resolutions, ensuring governance flexibility and efficiency, thereby enhancing decision-making speed and responsiveness to market changes.
- Business Development Context: Burning Rock focuses on the application of next-generation sequencing technology in precision oncology, with operations including NGS-based therapy selection testing for late-stage cancer patients and cancer early detection, marking progress into clinical validation and further solidifying its market position.
See More
Burning Rock Biotech Q1 Financial Results Analysis
- Net Loss Overview: Burning Rock Biotech reported a net loss of RMB 17.5 million (approximately $2.5 million) for Q1 2026, indicating challenges in profitability that may impact investor confidence moving forward.
- Revenue Decline: The company's revenue for the first quarter was $15.65 million, reflecting a 14.7% year-over-year decrease from $18.1 million in Q1 2025, highlighting pressures from weakened market demand and increased competition.
- GAAP EPS Report: The reported GAAP EPS was -$0.02, suggesting that the company continues to experience negative growth in profitability, which could affect its future financing capabilities and market performance.
- Historical Financial Data: Historical earnings data shows that revenue for Q1 2025 was RMB 133.1 million (approximately $19.5 million), while Q1 2026 revenue dropped to RMB 107.9 million (approximately $15.65 million), indicating a concerning trend of declining revenues.
See More
Burning Rock CEO Yusheng Han Purchases $546K in ADSs, Signaling Confidence
- Share Purchase: Yusheng Han, founder and CEO of Burning Rock Biotech, purchased 31,487 ADSs in the open market for $546,603.90, demonstrating his confidence in the company's future growth.
- Cumulative Holdings: With an additional 41,246 ADSs acquired in the previous post-earnings trading window, Han's total purchases amount to 72,733 ADSs for $1,358,325.18, reflecting his strong belief in the company's business prospects.
- Future Acquisition Plans: Han may continue to acquire the company's ADSs through open-market transactions, privately negotiated deals, or block trades, with the timing and conditions influenced by market conditions and regulatory requirements.
- Company Overview: Burning Rock focuses on next-generation sequencing technology in precision oncology, offering NGS-based therapy selection testing for late-stage cancer patients and early cancer detection, which has progressed to clinical validation, indicating significant market potential.
See More
Burning Rock Biotech Reports Q4 and Full Year 2025 Financial Results
- Quarterly Financial Performance: Burning Rock Biotech reported a Q4 GAAP EPS of -$0.02 with revenues of $18.1 million and a net loss of RMB 15.4 million (approximately $2.2 million), indicating challenges faced during the company's transition.
- Annual Revenue Growth: Total revenue for 2025 reached RMB 539.6 million ($77.2 million), representing a 4.6% increase from RMB 515.8 million in 2024, reflecting the company's stability in the overall market.
- Laboratory Business Decline: Revenue from the central laboratory business was RMB 160.0 million ($22.9 million) in 2025, an 8.9% decrease from RMB 175.6 million in 2024, primarily due to a reduction in the number of tests, indicating a shift towards in-hospital testing and pharma R&D services.
- Pharma R&D Services Growth: Revenue from pharma research and development services increased to RMB 155.5 million ($22.2 million) in 2025, a 34.5% rise from RMB 115.7 million in 2024, demonstrating increased demand for development and testing services from pharma clients.
See More
Seeking Dividends? Explore Opportunities in Europe.
U.S. Dividend Seekers: Investors in the U.S. are encouraged to explore European markets for potential dividend opportunities.
European Market Appeal: European companies are offering attractive dividend yields, which may be appealing compared to U.S. counterparts.
Economic Factors: Factors such as currency fluctuations and economic recovery in Europe are influencing the attractiveness of these investments.
Investment Strategy: Diversifying into European dividends could enhance returns for U.S. investors seeking income.
See More
Burning Rock's CEO Yusheng Han Purchases $811,721 in ADS, Signaling Confidence
- Executive Purchase Signal: CEO Yusheng Han's acquisition of $811,721 in ADS from the open market indicates his confidence in the company's future, potentially enhancing investor trust in Burning Rock.
- Compliance in Trading: This purchase was conducted in accordance with applicable regulations and the company's insider trading policy, ensuring the legality and transparency of the transaction, which further enhances corporate governance.
- Potential for Continued Purchases: Han may continue to acquire ADS depending on market conditions, and this flexible purchasing strategy could help seize investment opportunities amid market fluctuations, thereby increasing shareholder value.
- Optimistic Business Outlook: The company focuses on the application of NGS technology in precision oncology, and with its transition into the clinical validation stage, it is expected to achieve business growth, attracting more investor interest.
See More
Burning Rock Biotech Secures All Resolutions at 2025 AGM
- Auditor Appointment Confirmation: Burning Rock Biotech's 2025 AGM ratified the appointment of Ernst & Young Hua Ming LLP as the auditor for the fiscal year ending December 31, 2025, ensuring financial transparency and compliance, which is expected to enhance investor confidence.
- Board Re-election: Shareholders re-elected Feng Deng and Licen Lisa Xu as directors, indicating trust in the current management team, which is likely to support the company's ongoing development and strategic execution in the precision oncology sector.
- Resolution Execution Authorization: Shareholders authorized directors to take necessary actions to implement the passed resolutions, ensuring governance flexibility and efficiency, thereby enhancing decision-making speed and responsiveness to market changes.
- Business Development Context: Burning Rock focuses on the application of next-generation sequencing technology in precision oncology, with operations including NGS-based therapy selection testing for late-stage cancer patients and cancer early detection, marking progress into clinical validation and further solidifying its market position.
See More
